| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 24 | 2022 | 419 | 2.290 |
Why?
|
| Blood Pressure | 19 | 2018 | 317 | 1.580 |
Why?
|
| Education, Graduate | 2 | 2023 | 10 | 1.460 |
Why?
|
| Venous Thromboembolism | 4 | 2023 | 27 | 1.370 |
Why?
|
| Echocardiography | 21 | 2020 | 100 | 1.360 |
Why?
|
| Hypertrophy, Left Ventricular | 13 | 2018 | 65 | 1.360 |
Why?
|
| Humans | 86 | 2025 | 14537 | 1.320 |
Why?
|
| Ventricular Function, Left | 15 | 2020 | 80 | 1.310 |
Why?
|
| Female | 75 | 2025 | 9103 | 1.300 |
Why?
|
| Pregnancy Complications, Cardiovascular | 8 | 2020 | 34 | 1.260 |
Why?
|
| Universities | 2 | 2019 | 34 | 1.220 |
Why?
|
| Biostatistics | 2 | 2019 | 4 | 1.170 |
Why?
|
| Research | 2 | 2019 | 65 | 1.130 |
Why?
|
| Adult | 57 | 2025 | 5913 | 1.090 |
Why?
|
| Biomedical Research | 2 | 2018 | 49 | 1.060 |
Why?
|
| Heart Ventricles | 13 | 2020 | 60 | 1.040 |
Why?
|
| Middle Aged | 49 | 2025 | 3601 | 0.930 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2018 | 47 | 0.910 |
Why?
|
| Male | 51 | 2023 | 6754 | 0.880 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 139 | 0.830 |
Why?
|
| Pregnancy | 21 | 2023 | 1862 | 0.830 |
Why?
|
| Peripartum Period | 6 | 2020 | 9 | 0.800 |
Why?
|
| Ventricular Remodeling | 6 | 2018 | 44 | 0.790 |
Why?
|
| Antihypertensive Agents | 5 | 2013 | 64 | 0.780 |
Why?
|
| Cardiomyopathy, Dilated | 4 | 2020 | 35 | 0.780 |
Why?
|
| Diabetes Complications | 1 | 2021 | 15 | 0.780 |
Why?
|
| Prospective Studies | 24 | 2023 | 1160 | 0.720 |
Why?
|
| Vascular Stiffness | 3 | 2015 | 41 | 0.700 |
Why?
|
| Cardiomyopathies | 6 | 2020 | 15 | 0.690 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2022 | 29 | 0.680 |
Why?
|
| South Africa | 35 | 2025 | 7596 | 0.680 |
Why?
|
| Obesity | 6 | 2017 | 367 | 0.660 |
Why?
|
| Arterial Pressure | 6 | 2021 | 35 | 0.660 |
Why?
|
| Health Occupations | 1 | 2019 | 4 | 0.660 |
Why?
|
| Heart Rate | 2 | 2020 | 32 | 0.660 |
Why?
|
| Predictive Value of Tests | 14 | 2020 | 188 | 0.650 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2019 | 11 | 0.600 |
Why?
|
| Laparoscopy | 3 | 2023 | 6 | 0.600 |
Why?
|
| Pulsatile Flow | 3 | 2015 | 14 | 0.590 |
Why?
|
| Stroke Volume | 10 | 2021 | 43 | 0.580 |
Why?
|
| Brachial Artery | 4 | 2015 | 29 | 0.580 |
Why?
|
| Capacity Building | 1 | 2018 | 32 | 0.570 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 39 | 0.570 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2017 | 13 | 0.570 |
Why?
|
| Heart Failure | 8 | 2017 | 38 | 0.570 |
Why?
|
| Pulse Wave Analysis | 7 | 2017 | 61 | 0.560 |
Why?
|
| Life Style | 1 | 2017 | 86 | 0.550 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 55 | 0.550 |
Why?
|
| Weight Gain | 1 | 2017 | 77 | 0.550 |
Why?
|
| Training Support | 1 | 2016 | 4 | 0.530 |
Why?
|
| Staff Development | 1 | 2016 | 3 | 0.530 |
Why?
|
| Writing | 1 | 2016 | 2 | 0.530 |
Why?
|
| Publishing | 1 | 2016 | 5 | 0.530 |
Why?
|
| Cross-Sectional Studies | 13 | 2022 | 1422 | 0.520 |
Why?
|
| Treatment Outcome | 11 | 2023 | 889 | 0.520 |
Why?
|
| Body Composition | 1 | 2017 | 153 | 0.520 |
Why?
|
| HIV Infections | 7 | 2022 | 5097 | 0.520 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 4 | 0.520 |
Why?
|
| Thrombosis | 3 | 2023 | 47 | 0.510 |
Why?
|
| Aorta | 5 | 2017 | 43 | 0.510 |
Why?
|
| Risk Factors | 11 | 2025 | 1475 | 0.500 |
Why?
|
| Galectin 3 | 1 | 2015 | 2 | 0.490 |
Why?
|
| Exercise | 1 | 2017 | 205 | 0.480 |
Why?
|
| Developing Countries | 1 | 2017 | 400 | 0.470 |
Why?
|
| Retrospective Studies | 6 | 2023 | 799 | 0.460 |
Why?
|
| Aged | 17 | 2025 | 1740 | 0.460 |
Why?
|
| Rheumatic Heart Disease | 3 | 2019 | 13 | 0.450 |
Why?
|
| Young Adult | 13 | 2022 | 2498 | 0.380 |
Why?
|
| Echocardiography, Doppler | 4 | 2017 | 18 | 0.370 |
Why?
|
| Clinical Competence | 2 | 2008 | 13 | 0.360 |
Why?
|
| Ventricular Function, Right | 3 | 2020 | 4 | 0.360 |
Why?
|
| Labor Stage, First | 2 | 2008 | 8 | 0.360 |
Why?
|
| Students | 2 | 2023 | 50 | 0.350 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 370 | 0.340 |
Why?
|
| Diuretics | 5 | 2008 | 16 | 0.340 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2020 | 5 | 0.340 |
Why?
|
| Age Factors | 9 | 2025 | 370 | 0.340 |
Why?
|
| C-Reactive Protein | 4 | 2015 | 96 | 0.330 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 6 | 2012 | 27 | 0.320 |
Why?
|
| Cohort Studies | 7 | 2025 | 967 | 0.320 |
Why?
|
| Anticoagulants | 4 | 2023 | 57 | 0.320 |
Why?
|
| Hysterectomy, Vaginal | 3 | 2023 | 7 | 0.310 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 30 | 0.310 |
Why?
|
| Calcium Channel Blockers | 4 | 2006 | 14 | 0.310 |
Why?
|
| Mitral Valve | 2 | 2019 | 12 | 0.310 |
Why?
|
| Palpation | 1 | 2008 | 1 | 0.300 |
Why?
|
| Labor Presentation | 1 | 2008 | 6 | 0.300 |
Why?
|
| Cranial Sutures | 1 | 2008 | 1 | 0.300 |
Why?
|
| Fetal Monitoring | 1 | 2008 | 13 | 0.300 |
Why?
|
| Skull | 1 | 2008 | 2 | 0.300 |
Why?
|
| Obstetric Labor Complications | 1 | 2008 | 25 | 0.290 |
Why?
|
| Labor, Obstetric | 1 | 2008 | 44 | 0.290 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 4 | 0.290 |
Why?
|
| Adiposity | 4 | 2014 | 96 | 0.280 |
Why?
|
| Hemodynamics | 2 | 2019 | 32 | 0.280 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 2 | 2020 | 2 | 0.270 |
Why?
|
| Collagen | 2 | 2018 | 23 | 0.270 |
Why?
|
| Biomarkers | 7 | 2020 | 327 | 0.270 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 4 | 0.250 |
Why?
|
| Cardiomegaly | 1 | 2005 | 8 | 0.250 |
Why?
|
| Africa | 2 | 2018 | 376 | 0.250 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 3 | 0.250 |
Why?
|
| Endometrial Neoplasms | 1 | 2025 | 2 | 0.240 |
Why?
|
| Infant, Newborn | 5 | 2022 | 1479 | 0.230 |
Why?
|
| Amlodipine | 1 | 2004 | 3 | 0.230 |
Why?
|
| Indapamide | 1 | 2004 | 4 | 0.230 |
Why?
|
| Perindopril | 1 | 2004 | 4 | 0.230 |
Why?
|
| Electrocardiography | 3 | 2020 | 35 | 0.230 |
Why?
|
| Anatomy | 1 | 2024 | 1 | 0.230 |
Why?
|
| Registries | 4 | 2013 | 91 | 0.230 |
Why?
|
| Pregnancy Outcome | 4 | 2018 | 117 | 0.230 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 253 | 0.230 |
Why?
|
| Circadian Rhythm | 1 | 2004 | 31 | 0.230 |
Why?
|
| Prevalence | 5 | 2021 | 1192 | 0.220 |
Why?
|
| Inflammation | 3 | 2022 | 104 | 0.210 |
Why?
|
| Burns | 1 | 2023 | 12 | 0.210 |
Why?
|
| Hunger | 1 | 2022 | 2 | 0.210 |
Why?
|
| Embolism | 1 | 2023 | 4 | 0.210 |
Why?
|
| Food Supply | 1 | 2022 | 29 | 0.210 |
Why?
|
| Fibrinolysis | 1 | 2022 | 3 | 0.200 |
Why?
|
| Body Mass Index | 6 | 2012 | 321 | 0.200 |
Why?
|
| Placenta | 1 | 2022 | 44 | 0.200 |
Why?
|
| Heart Diseases | 1 | 2022 | 19 | 0.200 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2022 | 5 | 0.200 |
Why?
|
| Regression Analysis | 6 | 2025 | 133 | 0.200 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 563 | 0.200 |
Why?
|
| Uterine Prolapse | 1 | 2021 | 3 | 0.190 |
Why?
|
| Technetium Tc 99m Mertiatide | 1 | 2021 | 1 | 0.190 |
Why?
|
| Radioisotope Renography | 1 | 2021 | 3 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2021 | 4 | 0.190 |
Why?
|
| Bullying | 1 | 2021 | 9 | 0.190 |
Why?
|
| Observer Variation | 3 | 2017 | 15 | 0.180 |
Why?
|
| Phenotype | 4 | 2020 | 158 | 0.180 |
Why?
|
| Ultrasonography | 4 | 2015 | 77 | 0.180 |
Why?
|
| Vasodilator Agents | 3 | 2007 | 11 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2021 | 115 | 0.180 |
Why?
|
| Chronic Disease | 2 | 2019 | 107 | 0.180 |
Why?
|
| Heart Atria | 2 | 2017 | 7 | 0.180 |
Why?
|
| Time Factors | 5 | 2017 | 507 | 0.180 |
Why?
|
| Systole | 6 | 2019 | 37 | 0.180 |
Why?
|
| Sex Factors | 3 | 2017 | 227 | 0.180 |
Why?
|
| Neoplasms | 1 | 2022 | 147 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2020 | 1 | 0.170 |
Why?
|
| Blood Pressure Determination | 3 | 2015 | 27 | 0.170 |
Why?
|
| Acute Coronary Syndrome | 2 | 2010 | 13 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 171 | 0.170 |
Why?
|
| Case-Control Studies | 7 | 2021 | 480 | 0.170 |
Why?
|
| Diastole | 6 | 2018 | 43 | 0.170 |
Why?
|
| Adolescent | 9 | 2022 | 2985 | 0.170 |
Why?
|
| Resource Allocation | 1 | 2019 | 16 | 0.160 |
Why?
|
| Ventricular Pressure | 1 | 2018 | 5 | 0.160 |
Why?
|
| Survival Rate | 2 | 2017 | 96 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2018 | 4 | 0.150 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2018 | 4 | 0.150 |
Why?
|
| Myocardial Contraction | 1 | 2018 | 23 | 0.150 |
Why?
|
| Maternal Death | 1 | 2018 | 25 | 0.150 |
Why?
|
| Gadolinium DTPA | 1 | 2018 | 1 | 0.150 |
Why?
|
| Contrast Media | 1 | 2018 | 6 | 0.150 |
Why?
|
| Hysterectomy | 3 | 2023 | 9 | 0.150 |
Why?
|
| Renal Dialysis | 1 | 2018 | 27 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 37 | 0.150 |
Why?
|
| Myocardium | 1 | 2018 | 35 | 0.150 |
Why?
|
| Cytokines | 1 | 2018 | 107 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 253 | 0.140 |
Why?
|
| Sampling Studies | 2 | 2015 | 13 | 0.140 |
Why?
|
| HIV Seropositivity | 2 | 2010 | 265 | 0.140 |
Why?
|
| Aging | 2 | 2015 | 109 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 69 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2015 | 225 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2017 | 76 | 0.140 |
Why?
|
| Health Status | 1 | 2017 | 111 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 529 | 0.130 |
Why?
|
| Medical Staff | 1 | 2016 | 1 | 0.130 |
Why?
|
| Angiotensinogen | 3 | 2006 | 15 | 0.130 |
Why?
|
| Workload | 1 | 2016 | 13 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2015 | 29 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 62 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 217 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 2 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2015 | 57 | 0.120 |
Why?
|
| Longitudinal Studies | 4 | 2023 | 435 | 0.120 |
Why?
|
| Warfarin | 1 | 2014 | 19 | 0.120 |
Why?
|
| Bromocriptine | 2 | 2013 | 2 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2018 | 37 | 0.110 |
Why?
|
| Prognosis | 5 | 2014 | 199 | 0.110 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 12 | 0.110 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 17 | 0.110 |
Why?
|
| Germany | 3 | 2020 | 6 | 0.110 |
Why?
|
| Torsion Abnormality | 1 | 2012 | 1 | 0.100 |
Why?
|
| Disease Management | 1 | 2013 | 74 | 0.100 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 2 | 0.100 |
Why?
|
| African Americans | 1 | 2012 | 47 | 0.100 |
Why?
|
| Prolactin | 2 | 2010 | 4 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2023 | 34 | 0.100 |
Why?
|
| Pregnant Women | 2 | 2023 | 89 | 0.100 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2012 | 4 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 279 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2012 | 56 | 0.090 |
Why?
|
| Uterus | 2 | 2021 | 20 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2018 | 179 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 91 | 0.090 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2012 | 73 | 0.090 |
Why?
|
| Rotation | 3 | 2018 | 5 | 0.090 |
Why?
|
| Sepsis | 1 | 2012 | 102 | 0.090 |
Why?
|
| Thrombophilia | 1 | 2010 | 2 | 0.090 |
Why?
|
| Protein C | 1 | 2010 | 4 | 0.090 |
Why?
|
| Hormone Antagonists | 1 | 2010 | 1 | 0.090 |
Why?
|
| Abdominal Fat | 1 | 2009 | 6 | 0.080 |
Why?
|
| Factor VIII | 1 | 2010 | 54 | 0.080 |
Why?
|
| Incidence | 3 | 2017 | 685 | 0.080 |
Why?
|
| Fibrosis | 2 | 2020 | 11 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2017 | 64 | 0.080 |
Why?
|
| fas Receptor | 2 | 2005 | 13 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 237 | 0.080 |
Why?
|
| Nurses | 1 | 2009 | 32 | 0.080 |
Why?
|
| Puerperal Disorders | 1 | 2008 | 9 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 2008 | 9 | 0.080 |
Why?
|
| Interferon-gamma | 1 | 2008 | 39 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 44 | 0.080 |
Why?
|
| Software | 2 | 2021 | 37 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2008 | 89 | 0.080 |
Why?
|
| Cephalometry | 1 | 2008 | 2 | 0.070 |
Why?
|
| Dipyridamole | 1 | 2007 | 1 | 0.070 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2007 | 7 | 0.070 |
Why?
|
| Parity | 1 | 2008 | 19 | 0.070 |
Why?
|
| Exercise Test | 1 | 2007 | 13 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2007 | 12 | 0.070 |
Why?
|
| Body Height | 1 | 2008 | 52 | 0.070 |
Why?
|
| Antibodies, Anticardiolipin | 2 | 2022 | 9 | 0.070 |
Why?
|
| Birth Weight | 1 | 2008 | 80 | 0.070 |
Why?
|
| Waist Circumference | 3 | 2014 | 60 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 468 | 0.070 |
Why?
|
| Urban Population | 1 | 2009 | 257 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2009 | 472 | 0.070 |
Why?
|
| Cesarean Section | 1 | 2008 | 87 | 0.070 |
Why?
|
| Remission Induction | 1 | 2005 | 6 | 0.060 |
Why?
|
| Linear Models | 2 | 2017 | 83 | 0.060 |
Why?
|
| Pentoxifylline | 1 | 2004 | 13 | 0.060 |
Why?
|
| Verapamil | 2 | 2002 | 4 | 0.060 |
Why?
|
| Nifedipine | 2 | 2002 | 5 | 0.060 |
Why?
|
| Hydrochlorothiazide | 2 | 2002 | 9 | 0.060 |
Why?
|
| Enalapril | 2 | 2002 | 7 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 9 | 0.060 |
Why?
|
| Human Body | 1 | 2024 | 4 | 0.060 |
Why?
|
| Cadaver | 1 | 2024 | 5 | 0.060 |
Why?
|
| Tissue and Organ Procurement | 1 | 2024 | 14 | 0.060 |
Why?
|
| Mortality | 1 | 2025 | 104 | 0.060 |
Why?
|
| Cytochrome P-450 CYP11B2 | 1 | 2003 | 5 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 150 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2003 | 12 | 0.060 |
Why?
|
| Sodium Channels | 1 | 2003 | 6 | 0.060 |
Why?
|
| Point Mutation | 1 | 2003 | 16 | 0.060 |
Why?
|
| Burn Units | 1 | 2023 | 5 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2022 | 13 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 43 | 0.050 |
Why?
|
| Angiotensins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2023 | 11 | 0.050 |
Why?
|
| Enoxaparin | 1 | 2023 | 14 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 176 | 0.050 |
Why?
|
| Ghana | 1 | 2022 | 67 | 0.050 |
Why?
|
| Reference Values | 2 | 2012 | 64 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 1 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2022 | 2 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2022 | 3 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 36 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2022 | 107 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2023 | 72 | 0.050 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2022 | 4 | 0.050 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2022 | 4 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2022 | 5 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 24 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 99 | 0.050 |
Why?
|
| Uganda | 1 | 2022 | 197 | 0.050 |
Why?
|
| Vascular Resistance | 1 | 2021 | 12 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 385 | 0.050 |
Why?
|
| Antigens | 1 | 2021 | 11 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 8 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2021 | 12 | 0.050 |
Why?
|
| Sodium | 1 | 2021 | 30 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 21 | 0.050 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2001 | 4 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2013 | 19 | 0.050 |
Why?
|
| Health Surveys | 2 | 2012 | 59 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 296 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 411 | 0.040 |
Why?
|
| Heredity | 1 | 2020 | 6 | 0.040 |
Why?
|
| Pedigree | 1 | 2020 | 30 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 231 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 418 | 0.040 |
Why?
|
| HIV | 1 | 2022 | 380 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 82 | 0.040 |
Why?
|
| Genotype | 3 | 2006 | 442 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 9 | 0.040 |
Why?
|
| Procollagen | 1 | 2018 | 1 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2018 | 6 | 0.040 |
Why?
|
| Peptides | 1 | 2018 | 40 | 0.040 |
Why?
|
| Scotland | 1 | 2017 | 5 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2017 | 2 | 0.040 |
Why?
|
| Child | 1 | 2022 | 2242 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 34 | 0.030 |
Why?
|
| Manometry | 1 | 2015 | 12 | 0.030 |
Why?
|
| Nigeria | 1 | 2015 | 49 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2015 | 108 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 188 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 4 | 0.030 |
Why?
|
| Torque | 1 | 2014 | 1 | 0.030 |
Why?
|
| Community Health Services | 1 | 2014 | 58 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2014 | 57 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2014 | 43 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 149 | 0.030 |
Why?
|
| Maternal Mortality | 1 | 2014 | 58 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 79 | 0.030 |
Why?
|
| Body Constitution | 2 | 2003 | 8 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2014 | 353 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2014 | 147 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 2012 | 3 | 0.030 |
Why?
|
| Morbidity | 1 | 2012 | 37 | 0.030 |
Why?
|
| Papillary Muscles | 1 | 2012 | 1 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2012 | 1 | 0.020 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2012 | 1 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 8 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 51 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 45 | 0.020 |
Why?
|
| Cathepsin D | 1 | 2010 | 1 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2010 | 10 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 105 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 26 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2009 | 14 | 0.020 |
Why?
|
| Parturition | 1 | 2010 | 31 | 0.020 |
Why?
|
| Skinfold Thickness | 1 | 2009 | 6 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 31 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 23 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2009 | 29 | 0.020 |
Why?
|
| Leptin | 1 | 2009 | 26 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 133 | 0.020 |
Why?
|
| Auscultation | 1 | 2009 | 6 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 23 | 0.020 |
Why?
|
| Albuminuria | 1 | 2009 | 20 | 0.020 |
Why?
|
| Smoking | 1 | 2009 | 100 | 0.020 |
Why?
|
| Arteries | 1 | 2009 | 18 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2008 | 11 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 254 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2008 | 19 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2008 | 2 | 0.020 |
Why?
|
| Creatinine | 1 | 2008 | 53 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2008 | 7 | 0.020 |
Why?
|
| Overweight | 1 | 2009 | 87 | 0.020 |
Why?
|
| Apoptosis | 1 | 2008 | 40 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 150 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 4 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2007 | 2 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 146 | 0.020 |
Why?
|
| Renin | 1 | 2006 | 10 | 0.020 |
Why?
|
| Aldosterone | 1 | 2006 | 12 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2005 | 4 | 0.020 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2003 | 12 | 0.010 |
Why?
|
| Epithelial Sodium Channels | 1 | 2003 | 2 | 0.010 |
Why?
|
| Outpatients | 1 | 2003 | 38 | 0.010 |
Why?
|
| Methyldopa | 1 | 2002 | 2 | 0.010 |
Why?
|
| HIV-1 | 1 | 2009 | 1260 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2002 | 120 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2001 | 163 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 1324 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 127 | 0.010 |
Why?
|